G+C Research Group
Welcome,         Profile    Billing    Logout  
 3 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oms, Juan D
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
Garcia, Jacqueline
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
61
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
NCT05046561: Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Recruiting
2
598
US
STRI Formula, Placebo
Eyecheck, Inc.
Covid19
12/22
08/23
NCT06660368: BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Not yet recruiting
2
52
US
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax
H. Lee Moffitt Cancer Center and Research Institute, AbbVie
Relapsed or Refractory Acute Myeloid Leukemia (AML)
11/27
11/27
NCI-2018-00921, NCT03471260: Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Checkmark Data from P1b/2 study in combination with Venclexta with or without azacitidine for hematological malignancies at ASCO 2020
May 2020 - May 2020: Data from P1b/2 study in combination with Venclexta with or without azacitidine for hematological malignancies at ASCO 2020
Recruiting
1/2
96
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Ivosidenib, AG-120, Tibsovo, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
09/25
09/25
NCT03613532: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Recruiting
1
100
US
Venetoclax, ABT199, Fludarabine, Fludara, Busulfan, Busulfex, Myleran, Azacitidine, Decitabine/cedazuridine
Jacqueline Garcia, MD, National Institutes of Health (NIH)
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
02/25
02/26
NCT02890329: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Active, not recruiting
1
54
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy
National Cancer Institute (NCI)
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
10/22
08/25
NCT06343805: A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Recruiting
1
76
US
AJ1-11095
Ajax Therapeutics, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, PMF, PPV-MF, PET-MF
10/26
02/27
NCT03974217: Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Recruiting
1
12
US
Talazoparib, Talzenna, Decitabine, Dacogen
Dana-Farber Cancer Institute, Pfizer
Leukemia
12/24
06/25
NCT05455294: Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Active, not recruiting
1
16
US
Navitoclax, ABT-263, Venetoclax, Venclexta, Decitabine, Dacogen
Jacqueline Garcia, MD, AbbVie
Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
12/24
12/26
Schultz, James
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
Alvarez, Alina
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
NCT05930210: A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

Recruiting
3
230
US, RoW
ENERGI-F703 GEL, ENERGI-F703 matched vehicle
Energenesis Biomedical Co., Ltd.
Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
07/24
12/24
NCT05046561: Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Recruiting
2
598
US
STRI Formula, Placebo
Eyecheck, Inc.
Covid19
12/22
08/23
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
02/25
04/25
HORIZON, NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH

Recruiting
2
246
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Nonalcoholic Fatty Liver Disease
09/25
12/25
Michael, Peter
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27
Elsamre, Mohamed
NCT05860959: SUBLOCADE Long-term Outcomes

Recruiting
N/A
1200
Europe, Canada, US, RoW
Indivior Inc.
Opioid Use Disorder
08/27
08/27

Download Options